BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
about
Bromodomain Inhibitor Review: Bromodomain and Extra-terminal Family Protein Inhibitors as a Potential New Therapy in Central Nervous System TumorsThe bromodomain: from epigenome reader to druggable targetThe Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous ProteinsInhibition of BET bromodomains as a therapeutic strategy for cancer drug discoveryTargeting BET bromodomains for cancer treatmentBromodomains: Translating the words of lysine acetylation into myelin injury and repairInhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.The bromodomain inhibitor JQ1 triggers growth arrest and apoptosis in testicular germ cell tumours in vitro and in vivo.The BET bromodomain inhibitor I-BET151 acts downstream of smoothened protein to abrogate the growth of hedgehog protein-driven cancers.Inhibition of bromodomain proteins for the treatment of human diffuse large B-cell lymphoma.The Phosphoinositide 3-Kinase p110α Isoform Regulates Leukemia Inhibitory Factor Receptor Expression via c-Myc and miR-125b to Promote Cell Proliferation in Medulloblastoma.The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains.Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4.Induction of USP17 by combining BET and HDAC inhibitors in breast cancer cellsTargeting the EWS-ETS transcriptional program by BET bromodomain inhibition in Ewing sarcoma.MCM5 as a target of BET inhibitors in thyroid cancer cellsTargeting BET bromodomain proteins in solid tumorsPharmacological targeting of BET proteins inhibits renal fibroblast activation and alleviates renal fibrosisCharacterization of pancreatic glucagon-producing tumors and pituitary gland tumors in transgenic mice overexpressing MYCN in hGFAP-positive cells.Targeting tachykinin receptors in neuroblastoma.OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations.Twist-BRD4 complex: potential drug target for basal-like breast cancer.Target and Agent Prioritization for the Children's Oncology Group-National Cancer Institute Pediatric MATCH Trial.BET inhibitors: a novel epigenetic approach.An epigenetic gateway to brain tumor cell identity.Regulation of prostate cancer progression by the tumor microenvironment.Epigenetics: A primer for clinicians.Ubenimex enhances Brd4 inhibition by suppressing HEXIM1 autophagic degradation and suppressing the Akt pathway in glioma cells.Bromodomain and extraterminal protein inhibitors in pediatrics: A review of the literature.Bromodomain inhibitors and cancer therapy: From structures to applications.Epigenetic modification in chromatin machinery and its deregulation in pediatric brain tumors: Insight into epigenetic therapies.A Novel Epi-drug Therapy Based on the Suppression of BET Family Epigenetic Readers.Suppression of BRD4 inhibits human hepatocellular carcinoma by repressing MYC and enhancing BIM expression.Sensitivity to cdk1-inhibition is modulated by p53 status in preclinical models of embryonal tumors.MYCN-targeting vaccines and immunotherapeutics.Histone Deacetylases as New Therapeutic Targets in Triple-negative Breast Cancer: Progress and PromisesBET protein inhibitor JQ1 inhibits growth and modulates WNT signaling in mesenchymal stem cells.Epigenetic regulation in medulloblastoma.Epigenetic Drivers in Pediatric Medulloblastoma.Advances in Genomics Explain Medulloblastoma Behavior at the Bedside.
P2860
Q26744268-3E99F412-235D-4CFC-ACCD-287079369B88Q26999935-B984FAD4-1AFE-43E7-8018-4B0C3D72C294Q28073961-5EA2E9A0-CD31-4C13-90C9-9FDD1C05173DQ28260105-4A9AE43F-3E1A-44C4-980F-E6A2BA6FFE5EQ28263519-DFAED41B-D0C5-476B-98F1-12E8274224F7Q28268681-09FE2619-EAF9-4FDF-AC9A-29E633D0D43AQ33756997-EA67BF40-B689-4829-8F92-81C72ED3193FQ33844624-324B539A-F919-408B-AB58-39C935C07BABQ34738018-B4B71A17-9F1F-44F7-AD62-B0D80C3CA4A7Q34860750-B1BB292D-60C1-47BF-961D-B0D22E998F0AQ35542600-93C22E0E-B434-47CE-BE3C-A22B97C8FBF1Q35921820-689E3605-0562-4884-AD05-330EF7CB8DE9Q36310219-AB8A141D-893E-420F-A56C-210C1EC04AD2Q36545233-398E4504-1DE6-41E7-997C-81C5402C964AQ36738866-D8A5572D-E239-4896-84D7-126E35BB496BQ36965945-83CABD78-DC17-4304-BD8F-E09193DBEA17Q37619860-9E981762-B595-465E-8F87-04403CC6E98AQ37688355-8D277D34-3E52-48B6-A00F-92AF00575713Q37688783-7E872FC1-8227-4E60-A9A6-1119EF93A667Q37702248-6CFEEC5B-2634-4F43-B286-E2BD2B41BF9EQ37705651-584322FB-6D77-4B23-8EE2-7718BD4D90F4Q38288525-705086A7-6C48-43F9-9EF8-F22A743F0FD7Q38371672-2FEECD85-F14E-48CC-B06B-DBF1C002FCE1Q38609772-4B312F0A-0EA0-4493-958F-F113155077C8Q38682159-6826E0EC-1D7B-4A07-8CE3-43A346E3BCB8Q38717262-2A6161C1-AA3C-4F5F-A70C-20FE73677784Q38770916-267F364E-B0F3-4E0D-A863-DB9E69847048Q38796928-EB17E09A-16CD-49DA-90AD-A5F7536A8AFAQ39024306-C10F68A9-3189-4E75-9E3B-EF0031E6A11CQ39027056-B91BDBB3-B9D0-45AB-989C-7BF7B2B950C1Q39069889-9ABD458E-D655-4BF8-BE89-64DD42483E80Q39207675-D4C5331B-1DDF-4D6D-9B44-B711E69E37EAQ39924163-994D34D2-AA63-4F4A-A45D-EEA9E259BD20Q40883768-6B311F6A-D1F8-459F-95FF-D884E263014AQ41118615-7143F5EF-586B-457A-A261-1040C9E65DD4Q41664067-A62BF208-AB03-4ADD-920B-F397E08F0B5EQ42540751-AD1B202A-F4AE-4223-85A0-A3B19AA273A7Q47900778-182EB390-CC64-46B8-9EB0-FC7BA39BFBA7Q47949067-CDBEF1BE-B954-4123-B996-1AD1A1658511Q48116800-B26188FB-8BAF-4102-AD8A-CA3D249BC9B3
P2860
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
@en
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
@nl
type
label
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
@en
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
@nl
prefLabel
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
@en
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma.
@nl
P2093
P2860
P356
P1433
P1476
BET bromodomain protein inhibition is a therapeutic option for medulloblastoma
@en
P2093
Alexander Schramm
Andrea Odersky
Angelika Eggert
Anneleen Beckers
Anton Henssen
Gudrun Fleischhack
Johannes H Schulte
Kristina Althoff
Nicolai El-Hindy
Simon Schäfers
P2860
P304
P356
10.18632/ONCOTARGET.1534
P407
P577
2013-11-01T00:00:00Z